The following table summarizes the development stage and status of Calliditas’ portfolio of product candidates:
In addition, Calliditas have in-licensed Budenofalk 3 mg oral capsules and intend to develop Budenofalk in the United States for the treatment of AIH, subject to regulatory feedback. Calliditas plan to discuss the development plans with the FDA for AIH in 2020. In 2019, Calliditas entered into an agreement with Everest Medicines pursuant to which it granted Everest an exclusive license to develop and commercialize Nefecon for IgAN in Greater China and Singapore. In other key territories such as Europe, the Company intends to commercialize Nefecon through either a broad regional partnership or on a country-by-country basis.